GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $3.85 Consensus PT from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been given a consensus rating of “Hold” by the fifteen analysts that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $3.8542.

A number of research firms recently issued reports on GDRX. Morgan Stanley decreased their price objective on GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. The Goldman Sachs Group decreased their price objective on GoodRx from $4.00 to $2.50 and set a “neutral” rating for the company in a report on Monday, March 2nd. JPMorgan Chase & Co. restated a “neutral” rating on shares of GoodRx in a research note on Friday, February 27th. Mizuho decreased their price target on GoodRx from $4.00 to $3.00 and set a “neutral” rating for the company in a research note on Friday, February 27th. Finally, Jefferies Financial Group downgraded GoodRx to a “hold” rating in a research note on Thursday, January 22nd.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Lazard Asset Management LLC grew its stake in GoodRx by 43.6% in the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock valued at $85,000 after purchasing an additional 5,201 shares in the last quarter. Brevan Howard Capital Management LP grew its stake in GoodRx by 7.7% in the third quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock valued at $404,000 after purchasing an additional 6,842 shares in the last quarter. Hirtle Callaghan & Co LLC lifted its position in shares of GoodRx by 60.3% in the fourth quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after buying an additional 6,869 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of GoodRx by 202.3% in the second quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after buying an additional 7,580 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of GoodRx in the third quarter valued at approximately $33,000. 63.77% of the stock is currently owned by institutional investors.

GoodRx Trading Down 1.8%

NASDAQ GDRX opened at $2.15 on Friday. The firm has a market cap of $736.53 million, a P/E ratio of 23.89, a P/E/G ratio of 1.51 and a beta of 1.47. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.61 and a quick ratio of 2.61. The stock’s 50-day moving average is $2.18 and its 200-day moving average is $2.80. GoodRx has a one year low of $1.77 and a one year high of $5.81.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.09 EPS for the quarter, hitting analysts’ consensus estimates of $0.09. The company had revenue of $194.79 million for the quarter, compared to analyst estimates of $193.27 million. GoodRx had a return on equity of 9.31% and a net margin of 3.82%.GoodRx’s revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.09 earnings per share. Sell-side analysts anticipate that GoodRx will post 0.13 earnings per share for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.